CLT-28643抑制整合素α5β1可减少小鼠青光眼滤过手术模型的术后伤口愈合
研究在小鼠滤过手术模型中评估整合素α5β1小分子抑制剂CLT-28643的疗效,比较单次和重复结膜下注射(1或2 μg)及滴眼液(10 μg)与丝裂霉素C(MMC)0.02%的作用。结果显示CLT-28643疗效呈剂量依赖性,重复注射2 μg在滤过泡特征上优于MMC且无角膜毒性。
要点
- 整合素α5β1在术后早期滤过泡中高表达,CLT-28643可抑制该上调。
- CLT-28643对滤过泡面积和存活的影响呈剂量依赖性。
- 重复结膜下注射2 μg CLT-28643的疗效优于MMC 0.02%,且无角膜毒性。
核心结论
- 整合素α5β1抑制剂CLT-28643作为青光眼手术辅助治疗具有治疗潜力,在最佳剂量下可能比MMC具有更优的疗效和耐受性。
研究设计与样本
- 小鼠滤过手术模型,每组20只小鼠40只眼(n=40眼/组),比较单次和重复结膜下注射(1或2 μg)及滴眼液(10 μg)CLT-28643与MMC 0.02% 2分钟给药。
- 术后观察至28天,评估滤过泡大小、存活和毒性体征,并在术后第3、8、14、28天进行免疫组化分析血管生成、炎症、胶原沉积和整合素α5β1表达,所有评估由设盲观察者完成。
主要发现
- 免疫染色显示整合素α5β1在术后早期滤过泡中高表达,CLT-28643抑制了这种上调。
- CLT-28643对滤过泡面积和存活以及伤口愈合过程的疗效呈剂量依赖性。
- 单次注射2 μg CLT-28643对滤过泡特征的改善与10 μg滴眼液和MMC相似。
- 重复注射2 μg CLT-28643的疗效优于MMC,且无角膜毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the therapeutic potential of the small molecule integrin α5β1 inhibitor, CLT-28643, to improve the filtering surgery outcome in a mouse model. Different dose regimens and administration routes of the inhibitor were compared with mitomycin C (MMC), the gold standard in clin ical practice. METHODS: The efficacy of CLT-28643 on surgical outcome was studied in a mouse model for filtering surgery (n = 40 eyes from 20 mice per group). Single and repeated subconjunctival (SCJ) injections (1 or 2 μg) and topical eye drops (10 μg) of the integrin inhibitor were compared with 2-minute administration of MMC 0.02%. Bleb size, survival, and signs of toxicity were examined until 28 days after surgery. Immunohistochemical analysis of angiogenesis, inflammation, collagen deposition, and integrin α5β1 expression were performed on postoperative days 3, 8, 14, and 28. A masked observer performed all the assessments. RESULTS: Immunostaining showed that integrin α5β1 was highly expressed in the bleb at early time-points after surgery and that CLT-28643 inhibited this upregulation. Efficacy was shown to be dose-dependent for the integrin inhibitor CLT-28643 for bleb area and survival, and the wound healing process. While 2-μg single injection of CLT-28643 improved bleb characteristics in a similar way as 10-μg administered by eye drops and MMC, repeated injections of 2 μg showed superior efficacy compared to MMC, with no corneal toxicity. CONCLUSIONS: Administration of the integrin α5β1 inhibitor CLT-28643 has therapeutic potential as an adjunct to glaucoma surgery, possibly with a superior efficacy and tolerability compared with MMC when used at the optimal dose.
引用
- Van Bergen T, Zahn G, Caldirola P, et al. Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery. Invest Ophthalmol Vis Sci. 2016. PMID: 27893886. doi:10.1167/iovs.16-19751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。